Literature DB >> 12866370

Comparison of three methods for measuring factor VIII levels in plasma.

Wayne L Chandler1, Chris Ferrell, Joo Lee, Theingi Tun, Hien Kha.   

Abstract

We compared 1-stage clot-based, chromogenic, and immunoassay methods for measuring factor VIII in plasma with a focus on the measurement of elevated levels of factor VIII. The chromogenic assay showed the best interassay imprecision for factor VIII levels near 150 IU/dL. The best correlation was between the 1-stage clot-based and chromogenic factor VIII assays (r2 = 0.934), and the lowest correlation was between the 1-stage clot-based and antigenic factor VIII assays (r2 = 0.821). The presence of heparin, low-molecular-weight heparin, lepirudin, or lupus inhibitors in the sample resulted in major interference in the 1-stage clot-based assay but not the chromogenic or antigenic factor VIII assays. Overall, the chromogenic factor VIII activity assay was the optimal method, showing good precision, the best overall correlation with other assays, and no interference from heparin, low-molecular-weight heparin, lepirudin, or lupus inhibitors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12866370     DOI: 10.1309/C8T8-YNB4-G3W4-5PRF

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  12 in total

1.  The "normal" factor VIII concentration in plasma.

Authors:  Saulius Butenas; Behnaz Parhami-Seren; Anetta Undas; David N Fass; Kenneth G Mann
Journal:  Thromb Res       Date:  2010-05-07       Impact factor: 3.944

2.  A comparative study of the effects of temperature, time and factor VIII assay type on factor VIII activity in cryoprecipitate in Iran.

Authors:  Azadeh Omidkhoda; Mohammad Reza Tabatabaei; Kamran Atarodi; Kamran Karimi; Abbas Rahimi Froushani; Ali Akbar Pourfathollah
Journal:  Blood Transfus       Date:  2011-07-18       Impact factor: 3.443

3.  Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.

Authors:  C H Miller; A S Rice; B Boylan; A D Shapiro; S R Lentz; B M Wicklund; F M Kelly; J M Soucie
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824

4.  Method validation and clinical utility of chromogenic factor VIII assay compared to one-stage assay.

Authors:  Wilmare Gouws; Elsabie Botha; Adele Visser
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

5.  Recombinant Factor VIII Measurement in a Hemophilia A Patient Undergoing Cardiopulmonary Bypass-Supported Cardiac Surgery.

Authors:  Jennifer Bezaire; Dorothy Thomson; Erick McNair
Journal:  J Extra Corpor Technol       Date:  2018-09

6.  Clotting factor VIII (FVIII) and thrombin generation in camel plasma: A comparative study with humans.

Authors:  Abdel Galil M Abdel Gader; Abdul Karim M Al Momen; Abdulqader Alhaider; Marjory B Brooks; James L Catalfamo; Ahmed A Al Haidary; Mansour F Hussain
Journal:  Can J Vet Res       Date:  2013-04       Impact factor: 1.310

7.  Evaluation of Factor VIII as a Risk Factor in Indian Patients with DVT.

Authors:  Darpanarayan Hazra; Indrani Sen; Edwin Stephen; Sunil Agarwal; Sukesh Chandran Nair; Joy Mammen
Journal:  Surg Res Pract       Date:  2015-09-01

8.  International recommendations on the diagnosis and treatment of acquired hemophilia A.

Authors:  Andreas Tiede; Peter Collins; Paul Knoebl; Jerome Teitel; Craig Kessler; Midori Shima; Giovanni Di Minno; Roseline d'Oiron; Peter Salaj; Victor Jiménez-Yuste; Angela Huth-Kühne; Paul Giangrande
Journal:  Haematologica       Date:  2020-05-07       Impact factor: 9.941

9.  Should multiple factor dilutions be performed for all patient coagulation factor assays? Let the debate begin!

Authors:  Emmanuel J Favaloro; Leonardo Pasalic
Journal:  Res Pract Thromb Haemost       Date:  2022-03-13

10.  Educational Case: The Bleeding Patient.

Authors:  Isaac E McCool; Jeannie M Muir; Barbara E C Knollmann-Ritschel
Journal:  Acad Pathol       Date:  2019-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.